Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Zimmer Biomet Holdings Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.36 (market cap $77.43B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 4.6× Zimmer Biomet Holdings Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MDLZ | ZBH | |
|---|---|---|
Market Cap | $77.43B | $16.95B |
Volume | 7,695,104 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $103.98 |
52-Week Low | $51.51 | $79.58 |
Typical Hold Time | 107 Days | 89 Days |
Enterprise Value | $97.78B | $24.02B |
Dividend Yield | 3.43% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.41, up 1.73% with a bullish technical signal. The company shows strong fundamentals with consistent earnings beats, $38.54B in 2025 revenue, and improving cash flow. Analyst consensus is strongly bullish with a $70.29 price target. Recent developments include a dividend increase to $0.52 and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling investment case with solid profitability (8.86% net margin), attractive valuation (P/E 22.22), and strong analyst support. Key risks include cocoa cost pressures and competitive threats. The stock offers upside potential to consensus targets while providing defensive characteristics in volatile markets.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
